Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Zalcberg

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
BMJ (Clinical Research Ed.)|April 19, 2019
Seven electrocardiographs for seven clinical research studiesJohn R Zalcberg
The New England Journal of Medicine|August 21, 2018
Rationale, Opportunities, and Reality of Biosimilar MedicationsJohn R Zalcberg
Therapeutic Advances in Gastroenterology|May 5, 2021
Ripretinib for the treatment of advanced gastrointestinal stromal tumorJohn R Zalcberg
The Medical Journal of Australia|January 20, 2012
Comparative effectiveness research--a proposal for a new NHMRC funding streamJohn R Zalcberg
The Medical Journal of Australia|September 16, 2014
Broken doctor-patient relationships: why won't they listen?Michael Jefford, John R Zalcberg
Therapeutic Advances in Medical Oncology|September 4, 2012
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumorsDamien Kee, John R Zalcberg
Internal Medicine Journal|October 11, 2017
Do all services provided as part of a clinical trial require research ethics and governance review?Jeremy Kenner, John R Zalcberg
The Medical Journal of Australia|November 16, 2018
The value of participating in clinical trials: the whole is greater than the sum of its partsJohn R Zalcberg, Michael Friedlander
Seminars in Oncology|March 28, 2018
"Mind the Gap" RevisitedJohn R Zalcberg, Michael Wonder
Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Dose optimization of tyrosine kinase inhibitors to improve outcomes in GISTJohn R Zalcberg, Jayesh Desai
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
BMJ (Clinical Research Ed.)|April 19, 2019
Seven electrocardiographs for seven clinical research studiesJohn R Zalcberg
The New England Journal of Medicine|August 21, 2018
Rationale, Opportunities, and Reality of Biosimilar MedicationsJohn R Zalcberg
Therapeutic Advances in Gastroenterology|May 5, 2021
Ripretinib for the treatment of advanced gastrointestinal stromal tumorJohn R Zalcberg
The Medical Journal of Australia|January 20, 2012
Comparative effectiveness research--a proposal for a new NHMRC funding streamJohn R Zalcberg
The Medical Journal of Australia|September 16, 2014
Broken doctor-patient relationships: why won't they listen?Michael Jefford, John R Zalcberg
Therapeutic Advances in Medical Oncology|September 4, 2012
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumorsDamien Kee, John R Zalcberg
Internal Medicine Journal|October 11, 2017
Do all services provided as part of a clinical trial require research ethics and governance review?Jeremy Kenner, John R Zalcberg
The Medical Journal of Australia|November 16, 2018
The value of participating in clinical trials: the whole is greater than the sum of its partsJohn R Zalcberg, Michael Friedlander
Seminars in Oncology|March 28, 2018
"Mind the Gap" RevisitedJohn R Zalcberg, Michael Wonder
Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Dose optimization of tyrosine kinase inhibitors to improve outcomes in GISTJohn R Zalcberg, Jayesh Desai
Pageof 12